Tamoxifen and the induction of cancer

Carcinogenesis

Volumn 16, Issue 7, 1995, Pages 1449-1454

  King, C M ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; CARCINOGEN; CYTOCHROME P450; TAMOXIFEN;

BREAST TUMOR; CANCER RISK; CARCINOGENESIS; CELL DIVISION; DNA ADDUCT; DRUG ACTIVITY; DRUG METABOLISM; DRUG SAFETY; ENDOMETRIUM CANCER; GENE MUTATION; GENOTOXICITY; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER CARCINOGENESIS; LIVER MICROSOME; MITOSIS; MUTAGENESIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL; RETINOPATHY; REVIEW; TOXICOLOGY; UNSCHEDULED DNA SYNTHESIS;

ANIMAL; ANTICARCINOGENIC AGENTS; HUMAN; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; TAMOXIFEN;

EID: 0029012731     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/16.7.1449     Document Type: Review

References (42)

1. Anon, M. (1985) Consensus conference; Adjuvant chemotherapy for breast cancer. J. Am. Med. Assoc., 254, 3461-3463.
2. Henderson, B.E., Ross, R.K. and Pike, M.C. (1992) Hormonal chemo- prevention of cancer in women. Science, 259, 633-638.
3. Morse, A.M. and Stoner, G.D. (1993) Cancer chemoprevention: principles and prospects. Carcinogenesis, 14, 1737-1746.
4. Hirsimaki, P., Hirsimaki, Y., Nieminen, L. and Payne, B.J. (1993) Tamoxifen induces hepatocellular carcinoma in rat liver: a 1-year study with two antiestrogens. Arch. Toxicol., 67, 49-54.
5. Williams, G.M., Iatropoulos, M.J., Djordjevic, M.V. and Kaltenberg, O.P. (1993) The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis, 14, 315-317.
6. Greaves, P., Goonetilleke, R., Nunn, G., Topham, J. and Orton, T. (1993) Two- year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res., 53, 3919-3924.
7. Hardell, L. (1988) Pelvic irradiation and tamoxifen as risk factors for carcinoma of corpus uteri. Lancet, 2, no. 8625, 1432.
8. Van Leeuwen, F.E., Benraadt, J., Coebergh, J.W.W., Kiemeney, L.A.L.M., Gimbrere, C.H.F., Otter, R., Schouten, L.J., Damhuis, R.A.M., Bontenbal, M., Diepenhorst, F.W., Van den Belt-Dusebout, A.W. and Van Tinteren, H. (1994) Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet, 343, 448-452.
9. Fisher, B., Costantino, J.P., Redmond, C.K., Fisher, E.R., Wickerham, D.L. and Cronin, W.M. (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst., 86, 527-537.
10. Magriples, U., Naftolin, F., Schwartz, P.E. and Carcangiu, M.L. (1993) Highgrade endometrial carcinoma in tamoxifen-treated breast cancer patients. J. Clin. Oncol., 11, 485-490.
11. Pavlidis, N.A., Petris, C., Briassoulis, E, Klouvas, G., Psilas, C., Rempapis, J. and Petroutsos, G. (1992) Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. Cancer, 69, 2961-2964.
12. Fomander, T., Rutqvist, L.E., Cedermark, B., Glas, U., Mattsson, A., Silversward, J.D., Skoog, L., Somell, A., Theve, T., Wilking, N., Askergren, J. and Hjolman, M.L. (1989) Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet, 2. 117-120.
13. Powles, T.J., Jones, A.L., Ashley, S.E., O’Brien, M.E.R., Tidy, V.A., Treleavan, J., Cosgrove, D., Nash, A.G., Sacks, N., Baum, M., McKinna, J.A. and Davey, J.B. (1994) The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Br. Cancer Res. Treat., 31, 73-82.
14. Ching, C.K., Smith, P.G. and Long, R.G. (1992) Tamoxifen-associated hepatocellular damage and agranulocytosis. Lancet, 339, 940.
15. Pathak, D.N. and Bodell, W.J. (1994) DNA adduct formation by tamoxifen with rat and human liver microsomal activation systems. Carcinogenesis, 15, 529-532.
16. Rutqvist, L.E. and Mattsson, A. (1993) Cardiac and thromboembolic morbidity among postmenopausal women with early-state breast cancer in a randomized trial of adjuvant tamoxifen. J. Natl Cancer Inst., 85, 1398-1406.
17. Mike, V., Currie, V.E. and Gee, T.S. (1994) Fatal neutropenia associated with long-term tamoxifen therapy. Lancet, 344, 541.
18. Smith, R.P., Dewar, J.A. and Winter, J.H. (1993) Tamoxifen-induced asthma. Lancet, 341, 772.
19. Yager, J.D., Roebuck, B.D., Paluszcyk, T.L. and Memoli, V.A. (1986) Effects of ethinyl estradiol and tamoxifen on liver DNA turnover and new synthesis and appearance of gamma glutamyl transpeptidase-positive foci in female rats. Carcinogenesis. 7, 2007-2014.
20. Han, X. and Liehr, J.G. (1992) Induction of covalent DNA adducts inrodents by tamoxifen. Cancer Res., 52, 1360-1363.
21. White, I.N.H., De Matteis, F., Davies, A., Smith, L.L., Crofton-Sleigh, C., Venitt, S., Hewer, A. and Phillips, D.H. (1992) Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis, 13, 2197-2203.
22. Sargent, L.M., Dragan, Y.P., Bahnub, N., Wiley, J.E., Sattler, C.A., Schroeder, P, Sattler, G.L., Jordan, V.C. and Pitot, H.C. (1994) Tamoxifen induces hepatic aneuploidy and mitotic spindle disruption after a single in vivo administration to female Sprague-Dawley rats. Cancer Res., 54, 3357-3360.
23. Vancutsem, P.M., Lazarus, P. and Williams, G.M. (1994) Frequent and specific mutations of the rat pS3 gene in hepatocarcinomas induced by tamoxifen. Cancer Res., 54, 3864-3867.
24. Dragan, Y.P., Fahey, S., Street, K., Vaughan, J., Jordan, V.C. and Pitot, H.C. (1994) Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer F344 rats. Br. Cancer Res. Treat., 31, 11-25.
25. Fendl, K.C. and Zimniski, S.J. (1992) Role of tamoxifen in the induction of hormone-independent rat mammary tumors. Cancer Res., 52, 235-237.
26. Herbst, A.L., Ulfelder, H. and Poskanzer, D.C. (1971) Adenocarcinoma of the vagina: association of maternal stilbestrol therapy with tumor appearance in young women. New Engl. J. Med., 284, 878-881.
27. ARC (1987) Monographs on the Evaluation of Carcinogenic Risks to Humans. Overall Evaluation of Carcinogenicity: An Updating of I ARC Monographs Vols 1-42. I ARC, Lyon, pp. 272-310.
28. Liehr, J.G. (1990) Genotoxic effects of estrogens. Mutât. Res., 238, 269-276.
29. Liehr, J.G., Han, X. and Bhat, H.K. (1993) 32P-Postlabelling in studies of hormonal carcinogenesis. In Phillips, D.H., Castegnaro, M. and Bartsch, H. (eds). Postlabelling Methods for Detection of DNA Adducts. IARC, Lyon, pp. 149-155.
30. Ahotupa, M., Hirsimaki, P., Parssinen, R. and Mantyla, E. (1994) Alterations of drug metabolizing and antioxidant enzyme activities during tamoxifen- induced hepatocarcinogenesis. Carcinogenesis, 15, 863-868.
31. Styles, J.A., Davies, A., Lim, C.K., De Matteis, F., Stanley, L.A., White, I.N.H., Yuan, Z.-X. and Smith, L.L. (1994) Genotoxicity of tamoxifen, tamoxifen epoxide and loremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis, 15, 5-9.
32. Phillips, D.H., Hewer, A., White, I.N.H. and Farmer, P.B. (1994) Cochromatography of a tamoxifen epoxide-deoxyguanylic acid adduct with a major DNA adduct formed in the livers of tamoxifen-treated rats. Carcinogenesis, 15, 793-795.
33. Potter, G.A., McCague, R. and Jarman, M. (1994) A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism. Carcinogenesis, 15, 439-442.
34. Phillips, D.H., Potter, G.A., Horton, M.N., Hewer, A., Crofton-Sleigh, C., Jarman, M. and Venitt, S. (1994) Reduced genotoxicity of |D5-ethyl|-tamoxifen implicates a-hydroxylation of the ethyl group as a major pathway of tamoxifen activation to a liver carcinogen. Carcinogenesis, 15, 1487-1492.
35. Phillips, D.H., Carmichael, P.L., Hewer, A., Cole, K.J. and Poon, G.K. (1995) a-Hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes. Cancer Res., 54, 5518-5522.
36. Pathak, D.N., Pongracz, K. and Bodell, W.J. (1995) Microsomal and peroxidase activation of 4-hydroxy-tamoxifen to form DNA adducts: comparison with DNA adducts formed in Sprague-Dawley rats treated with tamoxifen. Carcinogenesis, 16, 11-15.
37. Randerath, K., Bi, J., Mabon, N., Sriram, P. and Moorthy, B. (1994) Strong intensification of mouse hepatic tamoxifen DNA adduct formation by pretreatment with the sulfotransferase inhibitor ! and ubiquitous environmental pollutant pentachlorophenol. Carcinogenesis, 15, 797-800.
38. Randerath, K., Moorthy, B., Mabon, N. and Sriram, P. (1994) Tamoxifen: evidence by 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite. Carcinogenesis, 15, 2087-2094.
39. Pitot, MC., Rareness, I, Doldsworthy, T and Kitagawa, I. (1978) Biochemical charaeteri/aiion of stage ol hepatocarcinogenesis after a single doseot diethylmtiosamme A'atute. 271, 456-458
40. Iniaida, K., Lee, MS., Wang, CY. and King, CM. (1991) Carcinogenicity ol dimtiopyienes in the weanling lemale CD rat CarcmooeneMs. 12. 1187-1191.
41. Moms, H P, Velat, CA., Wagner, BP., Dahlgaid, M. and Ray, FE. (1960) Studies ol carcinogenicity in the rat ol denvatives ol aromatic amines related to iV-2-lluorenylacetamide J Natl Cancer lnt. 24. 149-180.
42. Shirai, T., Fukushima, S., Ikawa, F., Tagawa, A. and Ito, N. (1986) Induction ol prostate carcinoma in wtu at high incidence in F544 rats by a combination ol 5.2’-dimethyl-4-ammohiphcnyl and ethinyl estradiol Canm Res. 46. 6425-6426.